105 related articles for article (PubMed ID: 38749728)
1. Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer.
Wasamoto S; Imai H; Tsuda T; Nagai Y; Kishikawa T; Ono A; Masubuchi K; Umeda Y; Yamada Y; Nakagawa J; Yui T; Taniguchi H; Kaira K; Kagamu H
Intern Med; 2024 May; ():. PubMed ID: 38749728
[TBL] [Abstract][Full Text] [Related]
2. Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.
Imai H; Wasamoto S; Tsuda T; Nagai Y; Kishikawa T; Masubuchi K; Osaki T; Miura Y; Umeda Y; Ono A; Minemura H; Yamada Y; Nakagawa J; Kozu Y; Taniguchi H; Ohta H; Kasai T; Kaira K; Kagamu H
Thorac Cancer; 2023 Sep; 14(25):2567-2578. PubMed ID: 37469246
[TBL] [Abstract][Full Text] [Related]
3. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
5. Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA.
Aggarwal H; Bayo K; Han Y; Muehlenbein CE; Zhu YE; Kim JS
Immunotherapy; 2023 Mar; 15(4):267-281. PubMed ID: 36789638
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.
Nishihara-Kato F; Imai H; Tsuda T; Wasamoto S; Nagai Y; Kishikawa T; Miura Y; Ono A; Yamada Y; Masubuchi K; Osaki T; Nakagawa J; Umeda Y; Minemura H; Kozu Y; Taniguchi H; Ohta H; Kaira K; Kagamu H
Oncology; 2024; 102(1):30-42. PubMed ID: 37598676
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S
Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
9. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Gadgeel S; Rodríguez-Abreu D; Speranza G; Esteban E; Felip E; Dómine M; Hui R; Hochmair MJ; Clingan P; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Garon EB; Novello S; Rubio-Viqueira B; Boyer M; Kurata T; Gray JE; Yang J; Bas T; Pietanza MC; Garassino MC
J Clin Oncol; 2020 May; 38(14):1505-1517. PubMed ID: 32150489
[TBL] [Abstract][Full Text] [Related]
10. Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations.
Liao J; Liu C; Long Q; Wu X; Wang H; Yu H; Sun S; Zhang Y; Lin Y; Zhao X; Wang J
Front Oncol; 2021; 11():752545. PubMed ID: 34660317
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
Yang Y; Chen W; Dong L; Duan L; Gao P
Clin Transl Oncol; 2024 Apr; ():. PubMed ID: 38625495
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
[TBL] [Abstract][Full Text] [Related]
13. High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study.
Sumiyoshi I; Okabe T; Togo S; Takagi H; Motomura H; Ochi Y; Shimada N; Haraguchi M; Shibayama R; Fujimoto Y; Watanabe J; Iwai M; Kadoya K; Iwakami SI; Takahashi K
J Transl Med; 2021 Feb; 19(1):92. PubMed ID: 33639962
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.
Horinouchi H; Nogami N; Saka H; Nishio M; Tokito T; Takahashi T; Kasahara K; Hattori Y; Ichihara E; Adachi N; Noguchi K; Souza F; Kurata T
Cancer Sci; 2021 Aug; 112(8):3255-3265. PubMed ID: 34036692
[TBL] [Abstract][Full Text] [Related]
15. Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer.
Ibusuki R; Yoneshima Y; Hashisako M; Matsuo N; Harada T; Tsuchiya-Kawano Y; Kishimoto J; Ota K; Shiraishi Y; Iwama E; Tanaka K; Oda Y; Okamoto I
Transl Lung Cancer Res; 2022 Nov; 11(11):2208-2215. PubMed ID: 36519019
[TBL] [Abstract][Full Text] [Related]
16. Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study.
Jun N; Hanping W; Xiaoyan S; Yan X; Mengzhao W; Xiaotong Z; Li Z
Thorac Cancer; 2020 Jul; 11(7):1869-1875. PubMed ID: 32406994
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
Rodríguez-Abreu D; Powell SF; Hochmair MJ; Gadgeel S; Esteban E; Felip E; Speranza G; De Angelis F; Dómine M; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Kurata T; Yang J; Pietanza MC; Souza F; Garassino MC
Ann Oncol; 2021 Jul; 32(7):881-895. PubMed ID: 33894335
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189.
Gadgeel S; Gray JE; Rizzo MT; Peterson P; Kim JS; Rodríguez-Abreu D
JTO Clin Res Rep; 2022 Nov; 3(11):100389. PubMed ID: 36406000
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
[TBL] [Abstract][Full Text] [Related]
20. Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy.
Nakashima K; Murakami H; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Endo M; Takahashi T
Mol Clin Oncol; 2016 Nov; 5(5):575-578. PubMed ID: 27900087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
